| Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Y Peng, AJ Mentzer, G Liu, X Yao, Z Yin, D Dong, W Dejnirattisai, ... Nature immunology 21 (11), 1336-1345, 2020 | 1202 | 2020 |
| Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1138 | 2021 |
| Cross-reacting antibodies enhance dengue virus infection in humans W Dejnirattisai, A Jumnainsong, N Onsirisakul, P Fitton, ... Science 328 (5979), 745-748, 2010 | 1086 | 2010 |
| Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus W Dejnirattisai, P Supasa, W Wongwiwat, A Rouvinski, G Barba-Spaeth, ... Nature immunology 17 (9), 1102-1108, 2016 | 1038 | 2016 |
| Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever J Mongkolsapaya, W Dejnirattisai, X Xu, S Vasanawathana, ... Nature medicine 9 (7), 921-927, 2003 | 1020 | 2003 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 930 | 2022 |
| Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum C Liu, HM Ginn, W Dejnirattisai, P Supasa, B Wang, A Tuekprakhon, ... Cell 184 (16), 4220-4236. e13, 2021 | 758 | 2021 |
| Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement P Avirutnan, N Punyadee, S Noisakran, C Komoltri, S Thiemmeca, ... The Journal of infectious diseases 193 (8), 1078-1088, 2006 | 674 | 2006 |
| Antibody evasion by the P. 1 strain of SARS-CoV-2 W Dejnirattisai, D Zhou, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (11), 2939-2954. e9, 2021 | 658 | 2021 |
| Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum A Tuekprakhon, R Nutalai, A Dijokaite-Guraliuc, D Zhou, HM Ginn, ... Cell 185 (14), 2422-2433. e13, 2022 | 614 | 2022 |
| T cell responses to whole SARS coronavirus in humans CK Li, H Wu, H Yan, S Ma, L Wang, M Zhang, X Tang, NJ Temperton, ... The Journal of Immunology 181 (8), 5490-5500, 2008 | 570 | 2008 |
| Structural basis of potent Zika–dengue virus antibody cross-neutralization G Barba-Spaeth, W Dejnirattisai, A Rouvinski, MC Vaney, I Medits, ... Nature 536 (7614), 48-53, 2016 | 537 | 2016 |
| A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus W Dejnirattisai, W Wongwiwat, S Supasa, X Zhang, X Dai, A Rouvinski, ... Nature immunology 16 (2), 170-177, 2015 | 498 | 2015 |
| Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (8), 2201-2211. e7, 2021 | 491 | 2021 |
| MAIT cells are activated during human viral infections B Van Wilgenburg, I Scherwitzl, EC Hutchinson, T Leng, A Kurioka, ... Nature communications 7 (1), 11653, 2016 | 485 | 2016 |
| TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL GR Screaton, J Mongkolsapaya, XN Xu, AE Cowper, AJ McMichael, ... Current biology 7 (9), 693-696, 1997 | 434 | 1997 |
| New insights into the immunopathology and control of dengue virus infection G Screaton, J Mongkolsapaya, S Yacoub, C Roberts Nature Reviews Immunology 15 (12), 745-759, 2015 | 407 | 2015 |
| Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority … SAC Clemens, L Weckx, R Clemens, AVA Mendes, AR Souza, ... The Lancet 399 (10324), 521-529, 2022 | 392 | 2022 |
| Neutralization of SARS-CoV-2 by destruction of the prefusion spike J Huo, Y Zhao, J Ren, D Zhou, HME Duyvesteyn, HM Ginn, L Carrique, ... Cell host & microbe 28 (3), 445-454. e6, 2020 | 374 | 2020 |
| Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum W Dejnirattisai, RH Shaw, P Supasa, C Liu, ASV Stuart, AJ Pollard, X Liu, ... Lancet (London, England) 399 (10321), 234, 2022 | 368 | 2022 |
